U.S. markets closed
  • S&P 500

    4,655.27
    +60.65 (+1.32%)
     
  • Dow 30

    35,135.94
    +236.60 (+0.68%)
     
  • Nasdaq

    15,782.83
    +291.18 (+1.88%)
     
  • Russell 2000

    2,241.98
    -3.96 (-0.18%)
     
  • Crude Oil

    70.42
    +0.47 (+0.67%)
     
  • Gold

    1,786.50
    +1.30 (+0.07%)
     
  • Silver

    22.92
    +0.06 (+0.28%)
     
  • EUR/USD

    1.1298
    -0.0022 (-0.19%)
     
  • 10-Yr Bond

    1.5300
    +0.0480 (+3.24%)
     
  • GBP/USD

    1.3316
    -0.0022 (-0.17%)
     
  • USD/JPY

    113.7180
    +0.4080 (+0.36%)
     
  • BTC-USD

    58,005.21
    +672.61 (+1.17%)
     
  • CMC Crypto 200

    1,460.81
    +31.88 (+2.23%)
     
  • FTSE 100

    7,109.95
    +65.92 (+0.94%)
     
  • Nikkei 225

    28,283.92
    -467.70 (-1.63%)
     

Mirati Unveils Long-term Survival Data For Sitravatinib/Nivolumab Combo In Lung Cancer Patients

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Mirati Therapeutics Inc (NASDAQ: MRTX) has announced results from a post hoc exploratory analysis of the Phase 2 study, MRTX-500 of sitravatinib combined with Bristol-Myers Squibb Co's (NYSE: BMY) Opdivo (nivolumab).

  • The trial included 68 patients with second or third-line non-squamous non-small cell lung cancer (NSCLC) who experienced clinical benefit on a prior checkpoint inhibitor (CPI) and subsequent disease progression.

  • The data were presented at the European Society for Medical Oncology Congress (ESMO21) 2021.

  • The combination therapy posted a median progression-free survival (PFS) was 5.7 months.

  • The median overall survival was 14.9 months, with 56% and 32% of these patients alive at one year and two years, respectively.

  • The objective response rate was 18%, with 3% of patients achieving a complete response and 15% of patients achieving a partial response.

  • The median duration of response was 12.8 months.

  • The sitravatinib and nivolumab combination was well-tolerated and consistent with what was previously reported.

  • Grade 3/4 treatment-related adverse events (TRAEs) were reported in 66% of patients. The rate of TRAEs leading to discontinuation was 22%

  • Mirati says that the results support its ongoing Phase 3 SAPPHIRE study evaluating the combo therapy in NSCLC patients who are resistant to immune checkpoint inhibitor therapy.

  • Interim overall survival readout is expected in 2H of 2022.

  • Price Action: MRTX stock is up 2.28% at $178.01 during the market session on the last check Monday.

  • Check out our coverage of the European Society for Medical Oncology Congress (ESMO21).

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.